搜索
Chemomab Therapeutics Ltd
CMMB添加自选
2.270USD
+0.550+31.98%
收盘 07/02, 13:00（美东）报价延迟15分钟
65.38M总市值
13.03市盈率 TTM
关于 Chemomab Therapeutics Ltd 公司
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Chemomab Therapeutics Ltd简介
公司代码CMMB
公司名称Chemomab Therapeutics Ltd
上市日期Aug 14, 2012
CEOMor (Adi)
员工数量16
证券类型Depository Receipt
年结日Aug 14
公司地址Kiryat Atidim, Building 7
城市TEL AVIV-YAFO
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Israel
邮编6158002
电话972773310156
网址https://www.chemomab.com/
公司代码CMMB
上市日期Aug 14, 2012
CEOMor (Adi)
Chemomab Therapeutics Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
14.48K
+95.59%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Dr. David M. Weiner, M.D.
Dr. David M. Weiner, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Mr. Jack Lawler
Mr. Jack Lawler
Chief Development Officer
Chief Development Officer
--
--
名称
名称/职务
职务
持股
持股变动
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
14.48K
+95.59%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
常见问题
Chemomab Therapeutics Ltd的前五大股东是谁？
Chemomab Therapeutics Ltd 的前五大股东如下：Ms. Sigal Fattal, CPA
有多少机构持有Chemomab Therapeutics Ltd(CMMB)的股份？
截至2026Q1，共有33家机构持有Chemomab Therapeutics Ltd的股份，合计持有的股份价值约为402.96K，占公司总股份的5.60%。与2025Q4相比，机构持股有所增加，增幅为-450971.00。